| |  Online-Ressource |
|---|
| Verfasst von: | Rautenberg, Christina [VerfasserIn]  |
|---|
| | Stölzel, Friedrich [VerfasserIn] |
|---|
| | Röllig, Christoph [VerfasserIn] |
|---|
| | Stelljes, Matthias [VerfasserIn] |
|---|
| | Gaidzik, Verena [VerfasserIn] |
|---|
| | Lauseker, Michael [VerfasserIn] |
|---|
| | Kriege, Oliver [VerfasserIn] |
|---|
| | Verbeek, Mareike [VerfasserIn] |
|---|
| | Unglaub, Julia Marie [VerfasserIn] |
|---|
| | Thol, Felicitas [VerfasserIn] |
|---|
| | Krause, Stefan W. [VerfasserIn] |
|---|
| | Hänel, Mathias [VerfasserIn] |
|---|
| | Neuerburg, Charlotte [VerfasserIn] |
|---|
| | Vucinic, Vladan [VerfasserIn] |
|---|
| | Jehn, Christian-Friedrich [VerfasserIn] |
|---|
| | Severmann, Julia [VerfasserIn] |
|---|
| | Wass, Maxi [VerfasserIn] |
|---|
| | Fransecky, Lars [VerfasserIn] |
|---|
| | Chemnitz, Jens [VerfasserIn] |
|---|
| | Holtick, Udo [VerfasserIn] |
|---|
| | Schäfer-Eckart, Kerstin [VerfasserIn] |
|---|
| | Schröder, Josephine [VerfasserIn] |
|---|
| | Kraus, Sabrina [VerfasserIn] |
|---|
| | Krüger, William [VerfasserIn] |
|---|
| | Kaiser, Ulrich [VerfasserIn] |
|---|
| | Scholl, Sebastian [VerfasserIn] |
|---|
| | Koch, Kathrin [VerfasserIn] |
|---|
| | Henning, Lea [VerfasserIn] |
|---|
| | Kobbe, Guido [VerfasserIn] |
|---|
| | Haas, Rainer [VerfasserIn] |
|---|
| | Alakel, Nael [VerfasserIn] |
|---|
| | Röhnert, Maximilian-Alexander [VerfasserIn] |
|---|
| | Sockel, Katja [VerfasserIn] |
|---|
| | Hanoun, Maher [VerfasserIn] |
|---|
| | Platzbecker, Uwe [VerfasserIn] |
|---|
| | Holderried, Tobias A. W. [VerfasserIn] |
|---|
| | Morgner, Anke [VerfasserIn] |
|---|
| | Heuser, Michael [VerfasserIn] |
|---|
| | Sauer, Tim [VerfasserIn] |
|---|
| | Götze, Katharina S. [VerfasserIn] |
|---|
| | Wagner-Drouet, Eva [VerfasserIn] |
|---|
| | Döhner, Konstanze [VerfasserIn] |
|---|
| | Döhner, Hartmut [VerfasserIn] |
|---|
| | Schliemann, Christoph [VerfasserIn] |
|---|
| | Schetelig, Johannes [VerfasserIn] |
|---|
| | Bornhäuser, Martin [VerfasserIn] |
|---|
| | Germing, Ulrich [VerfasserIn] |
|---|
| | Schroeder, Thomas [VerfasserIn] |
|---|
| | Middeke, Jan Moritz [VerfasserIn] |
|---|
| Titel: | Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia |
|---|
| Verf.angabe: | Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia Marie Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Hänel, Charlotte Neuerburg, Vladan Vucinic, Christian-Friedrich Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Krüger, Ulrich Kaiser, Sebastian Scholl, Kathrin Koch, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian-Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A.W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Götze, Eva Wagner-Drouet, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder and Jan Moritz Middeke |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 04 October 2021 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 09.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Blood cancer journal |
|---|
| Ort Quelle: | London [u.a.] : Nature Publishing Group, 2011 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 11(2021), 10, Artikel-ID 164, Seite 1-8 |
|---|
| ISSN Quelle: | 2044-5385 |
|---|
| Abstract: | To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (<10−3) as measured by flow cytometry. After a median follow-up of 9.3 months, median overall survival (OS) was 21 months and 1-year OS rate 64%. In multivariate analysis, complex karyotype predicted lower response (p = 0.0001), while pretreatment with hypomethylating agents (p = 0.02) and adverse European LeukemiaNet 2017 genetic risk (p < 0.0001) were associated with lower OS. Allogeneic hematopoietic cell transplantation (allo-HCT) was performed in 116 patients (62%) resulting in promising outcome (median survival not reached, 1-year OS 73%), especially in MRD-negative patients (p = 0.048). With 69% of patients developing grade III/IV non-hematologic toxicity following induction and a day 30-mortality of 8% the safety profile was consistent with previous findings. These real-world data confirm CPX-351 as efficient treatment for these high-risk AML patients facilitating allo-HCT in many patients with promising outcome after transplantation. |
|---|
| DOI: | doi:10.1038/s41408-021-00558-5 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/s41408-021-00558-5 |
|---|
| | Volltext: https://www.nature.com/articles/s41408-021-00558-5 |
|---|
| | DOI: https://doi.org/10.1038/s41408-021-00558-5 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Haematological cancer |
|---|
| | Leukaemia |
|---|
| K10plus-PPN: | 178086180X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia / Rautenberg, Christina [VerfasserIn]; 04 October 2021 (Online-Ressource)
